Nebivolol – unique β-blocker with vasodilatory effect Review article
Article Sidebar
Published:
Mar 31, 2015
Keywords:
nebivolol, β-blocker, vasodilatory effect
Main Article Content
Abstract
Nebivolol is one of the most modern drugs from the group of β-blockers. It is characterized not only by the antihypertensive efficacy, but also by a number of additional actions, such as vasodilatation, improvement of endothelial function or neutral metabolic profile. Nebivolol is favorable and safe drug, which, according to the guidelines of the Polish Society of Hypertension, should be preferred in the treatment of hypertension. In this paper nebivolol is compared with other β-blockers, with highlighting its actions and their potential clinical significance.
Article Details
How to Cite
Szymański , F. M. (2015). Nebivolol – unique β-blocker with vasodilatory effect. Medycyna Faktow (J EBM), 8(1(26), 60-64. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2325
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Gaciong Z., Narkiewicz K.: Leki β-adrenolityczne w terapii nadciśnienia tętniczego. Nadciśnienie Tętnicze 2008; (supl. E): E1-E24.
2. Filipiak K.J., Opolski G.: Działania niepożądane i środki ostrożności przy stosowaniu leków β-adrenolitycznych – spojrzenie z perspektywy 2005 roku. Choroby Serca i Naczyń 2005; 2(3): 157-169.
3. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34: 2159-2219.
4. Widecka K., Grodzicki T., Narkiewicz K et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15: 55-82.
5. Grodzicki T., Januszewicz A., Opolski G. (red.).: Leki beta-adrenolityczne w chorobach układu sercowo-naczyniowego. Via Medica, Gdańsk 2004.
6. De Groot A., Mathy M., van Zwieten P. et al.: Involvment of the beta3 adrenoreceptor in nebivolol-induces vasorelaxation in the rat aorta. J. Cardiovasc. Pharmacol. 2003; 42: 232-236.
7. Kamp O., Metra M., Bugatti S. et al.: Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Drugs 2010; 70: 41-56.
8. Kuroedov A., Cosentino F., Luscher T.F.: Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. Cardiovasc. Drug Rev. 2004; 22: 155-168.
9. Rozec B., Erfanian M., Laurent K. et al.: Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J. Am. Coll. Cardiol. 2009; 53: 1532-1538.
10. Dessy C., Saliez J., Ghisdal P. et al.: Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005; 112: 1198-1205.
11. Balligand J.L.: Beta(3)-adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade ‘‘stop or encore?’’. J. Am. Coll. Cardiol. 2009; 53: 1539-1542.
12. Prisant L.M.: Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker. J. Clin. Pharmacol. 2008; 48: 225-239.
13. Doumas M., Tsakiris A., Douma S. et al.: Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian J. Androl. 2006; 8: 177-182.
14. Tobe S.W.: β-Adrenergic Receptor Blockers in Hypertension. Can. J. Cardiol. 2014; 30: S1-S2.
15. Kasprzak J.D., Stępińska J., Wożakowska-Kapłon B. et al.: Polish Cardiac Society Working Group on Cardiovascular Drug Therapy. Optimum heart rate – the current goal of cardiovascular therapy. Position statement of the Polish Cardiac Society Working Group on Cardiovascular Drug Therapy. Kardiol. Pol. 2012; 70: 1081-1094.
2. Filipiak K.J., Opolski G.: Działania niepożądane i środki ostrożności przy stosowaniu leków β-adrenolitycznych – spojrzenie z perspektywy 2005 roku. Choroby Serca i Naczyń 2005; 2(3): 157-169.
3. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34: 2159-2219.
4. Widecka K., Grodzicki T., Narkiewicz K et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15: 55-82.
5. Grodzicki T., Januszewicz A., Opolski G. (red.).: Leki beta-adrenolityczne w chorobach układu sercowo-naczyniowego. Via Medica, Gdańsk 2004.
6. De Groot A., Mathy M., van Zwieten P. et al.: Involvment of the beta3 adrenoreceptor in nebivolol-induces vasorelaxation in the rat aorta. J. Cardiovasc. Pharmacol. 2003; 42: 232-236.
7. Kamp O., Metra M., Bugatti S. et al.: Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. Drugs 2010; 70: 41-56.
8. Kuroedov A., Cosentino F., Luscher T.F.: Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. Cardiovasc. Drug Rev. 2004; 22: 155-168.
9. Rozec B., Erfanian M., Laurent K. et al.: Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J. Am. Coll. Cardiol. 2009; 53: 1532-1538.
10. Dessy C., Saliez J., Ghisdal P. et al.: Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005; 112: 1198-1205.
11. Balligand J.L.: Beta(3)-adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade ‘‘stop or encore?’’. J. Am. Coll. Cardiol. 2009; 53: 1539-1542.
12. Prisant L.M.: Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker. J. Clin. Pharmacol. 2008; 48: 225-239.
13. Doumas M., Tsakiris A., Douma S. et al.: Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian J. Androl. 2006; 8: 177-182.
14. Tobe S.W.: β-Adrenergic Receptor Blockers in Hypertension. Can. J. Cardiol. 2014; 30: S1-S2.
15. Kasprzak J.D., Stępińska J., Wożakowska-Kapłon B. et al.: Polish Cardiac Society Working Group on Cardiovascular Drug Therapy. Optimum heart rate – the current goal of cardiovascular therapy. Position statement of the Polish Cardiac Society Working Group on Cardiovascular Drug Therapy. Kardiol. Pol. 2012; 70: 1081-1094.